Metformin: Diamonds are forever

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2395-2397

  Papanas, N ^a   Maltezos, E ^a   Mikhailidis, D P ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes mellitus; Metformin; Oral hypoglycaemic agents

Indexed keywords

LIPID; METFORMIN; PLACEBO;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIARRHEA; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; WEIGHT REDUCTION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN;

EID: 70349387862     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903176453     Document Type: Review

References (21)

1. Fox GN. Metformin in type2 diabetes. J Fam Pract 2004;53:900
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30 •• Joint guidelines by the American Diabetes Association and the European Association for the Study of Diabetes on the management of T2DM suggesting that metformin should be used alongside lifestyle modification as first-line agent at diagnosis of T2DM.
3. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009. In press
4. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type2 diabetes. Expert Opin Pharmacother 2008;9:1705-1720
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type2 diabetes (UKPDS 34). Lancet 1998;352:854-65 •• Landmark study showing that metformin significantly reduces cardiovascular morbidity in T2DM.
6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type2 diabetes. N Engl J Med 2008;359:1577-89 •• Follow-up study of UKPDS confirming that the beneficial effect of metformin on cardiovascular morbidity was sustained at 20 years.
7. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-80 •• Recent systematic review on the effect of oral hypoglycaemic agents on cardiovascular disease.
8. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;3:CD002966
9. Wulffelé MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004;256:1-14 (Pubitemid 38813614)
10. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-883 (Pubitemid 43875555)
11. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician 2009;79:671-676
12. Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-572 (Pubitemid 38525165)
13. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab 2009;11:338-342
14. Feher MD, Al-Mrayat M, Brake J, Sun Leong K. Tolerability of prolonged-release metformin (Glucophage SR) in individuals intolerant to standard metformin - results from four UK centres. Br J Diabetes Vasc Dis 2007;7:225-228 (Pubitemid 350055240)
15. Fantus IG. Metformin's contraindications: needed for now. CMAJ 2005;173:505-507
16. Papanas N, Monastiriotis C, Christakidis D, Maltezos E. Metformin and lactic acidosis in patients with type 2 diabetes-from pride and prejudice to sense and sensibility. Acta Clin Belg 2009;64:42-48
17. Salpeter SR, Greyber E, Pasternak G, Salpeter E. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;1:CD002967
18. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005;48:2454-2459
19. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-625
20. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-590 (Pubitemid 40216485)
21. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-228